Biotech | February 17, 2022
Kato wins USFDA approval for studies in retinal disorder
Resolv ER may remedy leading causes of blindness in adults
Resolv ER may remedy leading causes of blindness in adults
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Key takeaways of Q3FY22 quarter & conference call highlights
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Vonage Communications APIs allow developers to easily enhance and build intelligent, intuitive customer experiences directly into their existing applications and devices
Subscribe To Our Newsletter & Stay Updated
